Conatus Pharmaceuticals (CNAT) Gains on WSJ Zika-Related Mention
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Conatus Pharmaceuticals (NASDAQ: CNAT) surges following WSJ mention related to Zika. Shares up 15%.
The article discusses liver-disease drug emricasan for use to quell the Zika virus, which Conatus holds several patents on.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Advises Patients With St. Jude Medical (STJ) Heart Implants to Continue Using Devices - Reuters
- ARIAD Pharma (ARIA) volatility continues to move higher as shares trend lower
- Facebook (FB) November weekly 140 calls active into Q3 and outlook
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!